Antonio Lombardi

TL;DR: Daily treatment with alendronate progressively increases the bone mass in the spine, hip, and total body and reduces the incidence of vertebral fractures, the progression of vertebra deformities, and height loss in postmenopausal women with osteoporosis.

TL;DR: The results suggest that for many women, discontinuation of alendronate for up to 5 years does not appear to significantly increase fracture risk, however, women at very high risk of clinical vertebral fractures may benefit by continuing beyond 5 years.

TL;DR: In this article, the effect of 10 mg of alendronate or placebo, given daily, on bone mineral density in 241 men with osteoporosis, was studied in a double-blind trial.

TL;DR: In this article, the effects of oral alendronate, an aminobisphosphonate, on bone mineral density and the incidence of fractures and height loss in 994 women with postmenopausal osteoporosis were studied.

TL;DR: Alendronate and estrogen produced favorable effects on BMD, biochemical markers of bone turnover, safety, and tolerability in 425 hysterectomized postmenopausal women with low bone mass, and combined use of alendronates and estrogenproduced somewhat larger increases in BMD than either agent alone and was well tolerated.